AzTrials
AzTrials

MalariaPhase 4NCT01403350

Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan

A Phase 4 study testing Malaria Rapid Diagnostic test in people with Malaria and Fever, run by London School of Hygiene and Tropical Medicine at 3 sites in Afghanistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Malaria is a common, but decreasing, cause of fever in endemic areas. The use of rapid diagnostic tests could improve treatment of malaria at the local community level. Deployment of these tests is, however, a considerable cost. Read more about this study

Who is it for?
Any age
Conditions the study is for
Malaria, Fever, Acute Febrile Illness
What is being tested?
Malaria Rapid Diagnostic test
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,421 participants
Where
3 sitesAfghanistan
Study dates
Feb 2012to Aug 2012
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Any patient where the CHW* or clinician considers malaria in the diagnosis - either prescribing an antimalarial or would request a malaria test if available or referring for diagnosis of malaria elsewhere.
  • *any community health worker who consults with patients and prescribes treatment, and is administratively attached to one of the study clinics.
  • Patient, or parent/guardian, gives informed consent to the study.

Who cannot join

  • Patients with a diagnostic result from another facility.
  • Patients referred on for diagnosis in the private sector.
  • Patients who have signs of severe or complicated disease and are referred prior to giving any diagnosis using the interventions.

Trial locations and contacts

3 sites in 1 country.

Afghanistan3 sites
  • HealthNet TPO

    Jalalabad, Nangarhar

  • Health Protection and Research Organisation

    Kabul, 0000

  • Merlin

    Kunduz

Other trials in Afghanistan

About this study

Official title: Effectiveness of Community Level Deployment of Rapid Diagnostic Tests for Malaria in Afghanistan: Cluster Randomised Trial

Malaria is a common, but decreasing, cause of fever in endemic areas. The use of rapid diagnostic tests could improve treatment of malaria at the local community level. Deployment of these tests is, however, a considerable cost. The aim of the study is to evaluate their effect on improving treatment of fever when used by Community Health Workers in Afghanistan. In phase I of the study, the hypothesis is that an RDT diagnosis deployed with standard training and support will improve the accuracy of treatment applied to fever by community health workers when compared to a diagnosis that is based on symptoms alone. In Phase II of the study, the hypothesis is that the accuracy of treatment can be improved by additional training and supportive interventions given to community health workers compared to those who have only had standard training.

Read the detailed description

This is a cluster randomised trial conducted in 22 clinics (clusters) in two provinces of Afghanistan. Clinics in Afghanistan have a number of community health workers (CHWs) who are residents of villages near to the clinic. The clinic provides them with their supplies of drugs and other items (e.g. family planning interventions) and the CHW provides a range of services in the community including treatment of acute episodes of fever. Currently, the CHW has no way of diagnosing malaria, except based on the presenting signs and symptoms of the patient. With this method is it likely that many patients who do not have malaria, but have a fever, are treated with antimalarial drugs and some patients with malaria are likely not to be treated with an antimalarial drug.

The use of Rapid Diagnostic Tests (RDT) for malaria could potentially provide the CHW with an easy and safe way of diagnosing malaria based on the presence or absence of parasites in the blood. However, use of tests is not straightforward. They need to be applied correctly, following a strict protocol, to be accurate. There is now much interest in widespread deployment of these tools which are recommended by the World Health Organisation for all fever patients in malaria endemic areas. However, evidence for their effectiveness when used by CHWs is patchy and there are no randomised trials that have been conducted in Asia. Since they represent a considerable cost, examination of their effectiveness is required.

In Asia (unlike most of Africa), malaria is caused by two species - Plasmodium vivax accounts for the majority of cases and P. falciparum for the minority. Treatments differ between the species because of differing drug resistance patterns. Therefore accurate diagnosis is important for providing accurate treatment for the different types of malaria and also for treatment of cases of fever who do not have malaria with alternative treatments. In areas where health services are restricted by short opening hours, insecurity, or inaccessibility due to distance or terrain, the CHW should be able to use RDTs and apply the correct treatment for both a positive and a negative test at the village level.

This study will randomise 22 clinics (and their constituent CHWs) to receive either an RDT for use by the CHW in diagnosing malaria in patients with fever, or no intervention (the current situation) where CHWs base their treatment decisions on symptoms alone (i.e. there is no parasite based diagnosis). The RDT group will be given the standard national training for use of RDTs and management of malaria and the standard supplies. The non-RDT arm will have training on management of malaria and a short introduction to RDTs. The study will measure the accuracy of treatment applied by the CHW in the RDT vs. the non-RDT arms, and examine the accuracy of the RDT itself when it is applied in the field under operational conditions. The accuracy will be measured by collecting filter paper blood spots from the patients which will be tested by PCR for malaria. A variety of comparisons will be made between the two groups, but the main aim is to measure and difference in accurate treatment of the patients according to the reference (PCR) diagnosis.

In phase II of the study the non-RDT arm will be discontinued and the clinics will be re-randomised to different interventions. One group of clinics will have the standard RDT roll out continued, as previously, and the second group will get additional training and a range of supportive interventions to assist in their practice. The second phase will use the same methods of assessing the study outcomes. The aim of the second phase is to see whether additional training (and cost) results in improved practice by CHWs.

Being tested
Malaria Rapid Diagnostic test
Keywords
Malaria, Fever, Acute febrile illness, Pneumonia, Community health worker, Rapid diagnostic test
Medical subject headings
Malaria, Fever, Pneumonia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Malaria Rapid Diagnostic testDevice

    Also called RDT: CareStart Pf/Pan Rapid Diagnostic Test (national standard RDT)

    Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions

Study groups in NCT01403350
Study groupRoleWhat they receive
Current PracticeNo interventionStudy Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
Intervention ArmActive comparatorStudy Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
Receives: Device: Malaria Rapid Diagnostic test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of cases correctly treated

    Correctly treated defined as:

    Those with PCR positive blood sample given an appropriate antimalarial; Those with PCR negative blood sample not given any antimalarial

    Measured: Outcomes measured during consultation - approximately 30-40 minutes

Secondary outcomes (4)
  1. Proportion of falciparum patients treated with artesunate combination therapy

    Measured against the PCR result from the blood sample

    Measured: Outcomes measured during consultation - approximately 30-40 minutes

  2. Accuracy of the RDT

    Sensitivity and specificity measured against the PCR blood sample

    Measured: Outcomes measured during consultation - approximately 30-40 minutes

  3. Accuracy of treatment given by the CHW in response to the RDT result

    Proportion of patients with a positive RDT not given and appropriate antimalarial Proportion of patient with a negative RDT who are given any antimalarial

    Measured: Outcomes measured during consultation - approximately 30-40 minutes

  4. Cost effectiveness of the intervention(s)

    Comparative cost-effectiveness between the arms

    Measured: Outcomes measured during consultation - approximately 30-40 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jul 2011 (estimated)
  2. Study startFeb 2012
  3. Primary completionAug 2012
  4. Study completionAug 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,421 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01403350
Sponsor's protocol ID
5911
Status last verified
Feb 2014
First submitted
25 Jul 2011
Last updated
15 Jul 2022
Results posted
No
Data monitoring committee
Yes

Publications

  • Leslie T, Rowland M, Mikhail A, Cundill B, Willey B, Alokozai A, Mayan I, Hasanzai A, Baktash SH, Mohammed N, Wood M, Rahimi HU, Laurent B, Buhler C, Whitty CJM. Use of malaria rapid diagnostic tests by community health workers in Afghanistan: cluster randomised trial. BMC Med. 2017 Jul 7;15(1):124. doi: 10.1186/s12916-017-0891-8.

    PubMed 28683750

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Malaria Rapid Diagnostic test in people with Malaria and Fever, run by London School of Hygiene and Tropical Medicine at 3 sites in Afghanistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Afghanistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of cases correctly treated (time frame: Outcomes measured during consultation - approximately 30-40 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01403350, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in